Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 15,208 shares at $14.99 ($228K) on 2017-05-15, disclosed to the SEC on 2017-05-17.
Open-market sale of $228k ATRA by EVP, R&D & Chief Scientific Of. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.99 | 7,604 | $114K | 50.0% |
| 2 | $14.99 | 7,604 | $114K | 50.0% |
| Total | $14.99 avg | 15,208 | $228K | 100% |
| Filing → |
| ATRA | SELL | 2019-02-08 | $956K | — | Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |